Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Nykode Therapeutics Announces Strategic Repositioning Of VB10.16

Aug 21 (Reuters) - Nykode Therapeutics ASA  NYKD.OL :
    * NYKODE THERAPEUTICS ANNOUNCES STRATEGIC REPOSITIONING OF
VB10.16
TO FOCUS ON LOCALLY ADVANCED CERVICAL CANCER AND RECURRENT
METASTATIC HEAD AND NECK CANCER
    * NYKODE THERAPEUTICS ASA - DECISION IS EXPECTED TO REDUCE
VB10.16
DEVELOPMENT COSTS BY OVER $25 MILLION
    * NYKODE THERAPEUTICS ASA - DECIDED TO DISCONTINUE C-04
TRIAL

Source text for Eikon:  ID:nObizwdjna 
Further company coverage:  NYKD.OL 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Nykode Therapeutics ASA

See all news